Stock Ratings / Health Care / BDX / options

BSX (62) MDLN (44) RMD (86) MMM (65) ⌘ Pro Terminal →

Becton Dickinson and Company (BDX) Options Positioning, Max Pain & Unusual Sweeps

$197.88 -0.23% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $197.42

Becton Dickinson and Company (BDX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $54.03B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BDX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Becton Dickinson and Company (NYSE: BDX) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $197.88 (-0.23% 1D, market cap $54.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BDX ranks #105 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BDX compare to BSX and MDLN in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), BDX carries a Roarable C+ (67/100 RQD), trailing P/E of 32.2x, gross margin of 45.4%, and ROIC of 4.9%. By comparison, BSX (Boston Scientific Corporation) holds a C grade (62/100 RQD, P/E 22.0x, ROIC 9.2%, cap $61.87B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BDX?

▼

Per BDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000010795), Becton Dickinson and Company generated $21.84B in revenue (+8.2% YoY), $1.68B in net income, and $0 in free cash flow against $54.84B in total assets and $16.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $197.42 (-0.23%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 5.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BDX)Realized 20D OHLCV Swing Band: ±4.2%

Deterministic 5-Pillar Attribution (67/100 Composite)

🔍 WHY BDX SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (27% of score)

20D Institutional Volume Accumulation (±4.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (21% of score)

Altman Z-Score 2.22 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Cash Engine Quality10/20 pts (-10 pt drag)

Capital intensity & 11.8% operating margin leave 10 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$187.37+3.4% Next Q

Q2 (-2Q)

Grade C+$193.80+0.6% Next Q

Q3 (-1Q)

Grade C+$195.03+1.5% Next Q

Current

Grade C+$197.88+1.6% Hist 90D α

Trajectory: C (59) → C+ (67)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BDX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, BDX faces multiple-compression risk if 32.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 42.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($186.88) or 200D SMA ($166.33) invalidates the momentum regime and cuts Target Base ($205.89) toward Bear Floor ($160.59).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BDX Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 67%NO 33%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±4.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BDX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BDX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating BDX & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on BDX
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.25%⚡ TESTING RESISTANCE

2026-11-02O $195.2H $198.3L $195.2C $197.9VOL 2.20M

RES: $201.9SUP: $186.6SMA50: $186.9SMA200: $166.3

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BDX Butterfly Map → + Track BDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

24.9%/yr Implied 5Y Growth

vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BDX)

Health Care Rank #105 of 1016 ⚔️ BSX vs BDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BDX vs. BSX, MDLN, RMD, MMM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Becton Dickinson and Company (BDX) ranks #105 by composite RQD confidence (67/100, grade C+) and #37 by equity capitalization ($54.03B). Within this direct 5-issuer industry benchmark cohort, BSX leads on earnings valuation at 22.0x trailing P/E, while MMM leads on capital efficiency and profitability with 32.9% ROIC and 39.9% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with BDX at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BDX ACTIVE Becton Dickinson and Company	C+	67/100	32.2x	45.4%	4.9%	-0.23%	$54.03B	Benchmark Subject
BSX Boston Scientific Corporation	C	62/100	22.0x	69.0%	9.2%	-1.66%	$61.87B	/bsx-vs-bdx →
MDLN Medline Inc.	D	44/100	—	—	8.2%	+0.38%	$42.07B	/mdln-vs-bdx →
RMD ResMed Inc.	A	86/100	25.4x	59.4%	22.9%	-9.05%	$35.56B	/rmd-vs-bdx →
MMM 3M Company	C	65/100	28.2x	39.9%	32.9%	-1.70%	$91.65B	/mmm-vs-bdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000010795

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Becton Dickinson and Company (BDX) reported GAAP revenue of $21.84B (+8.2% vs. FY2024 revenue of $20.18B , and +12.7% cumulative change since FY2023) , GAAP net income of $1.68B, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BDX closed FY2025 with $54.84B in total assets against $16.92B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$21.84B	$1.68B	—	—	$54.84B	$16.92B
FY2024 (FY)	2024-09-30	$20.18B	$1.71B	—	—	$54.66B	$17.44B
FY2023 (FY)	2023-09-30	$19.37B	$1.48B	—	—	$29.71B	$6.95B

3. BDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BDX compare to BSX and MDLN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BDX?

Where is BDX trading relative to its 50-day, 200-day, and 52-week technical levels?

BDX last traded at $197.88 (-0.23% on volume of 2,920,047 shares), positioning the stock +5.89% above its 50-day simple moving average ($186.88) and +18.97% above its 200-day simple moving average ($166.33). Across its 52-week range of $127.59 to $200.47, BDX sits at the 96.4% percentile with a 14-day RSI of 64.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.2% ($189.57 to $206.19).

BDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BDX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BDX.

Direct Sub-Reports: BDX RQD Cockpit BDX 12M Forecast BDX Earnings & Move BDX Dividends & DRIP BDX Insiders & 13F BDX Whale Options BDX Profit Sankey BDX News & Why

ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BDX — Becton Dickinson and Company: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:10:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BDX scores 67 out of 100 (letter grade C+; verdict: Roarable Hold — Upper Neutral / Watch for Breakout). The five pillars are:

Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 4.9% and an FCF yield of 2.13%. Both figures are modest, which limits the cash-generation case for a higher score and implies that the current valuation (P/E TTM 32.2) relies heavily on expectations rather than cash returns on invested capital.
Whale / 13F Flow: 18 / 20. Per the Roarable RQD rating, this is the strongest pillar, described as institutional accumulation and options positioning. The source does not itemize the underlying 13F filings, so the size and timing of this accumulation cannot be verified here.
Insider Conviction: 12 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow at a moderate level. The individual transactions are not provided in the source data.
Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 1.06, indicating market-like volatility with a sector sensitivity component. An investor should expect the stock to move roughly in line with the broader market.
Forensic Balance Sheet: 14 / 20. Per the Roarable RQD rating, Altman Z is 2.22, Piotroski F is 8 of 9, and Debt/Equity is 0.67. Per the same rating, these metrics indicate a sound but not pristine balance sheet, with the Altman Z-Score in a range that does not signal distress.

Taken together, the rating points to a stock whose institutional support and balance sheet strength are offset by thin cash returns and a premium valuation. The verdict's "Watch for Breakout" language implies that the rating is awaiting a catalyst for re-rating, rather than signaling an immediate directional call. The price of 198.34 sits near the top of the 52-week range of $127.59 to $200.47 (per market data), so upside from current levels depends on continued execution and sentiment improvement. This is an analytical framing, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$198.34	$54.03B	32.2	29.9	21.8	6.16	2.21%	1.06	$127.59 - $200.47	4.9%

Business

Becton Dickinson and Company is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry (per the company profile). The source data does not describe its specific product lines, customer base, or revenue model. Per the SEC financials, the company reported FY 2025 revenue of $21840.0M, indicating a large-scale operation. Gross margin is 45.4% per market data.

Recent Catalysts & News Wire Analysis

Earnings quality question (RISK WATCH): A Yahoo Finance headline reports revenue growth of 5.4% alongside an earnings decline of 34.3%, asking why profit fell further than revenue.
Downgrade (RISK WATCH): A Seeking Alpha headline references a rating downgrade, describing fundamentals as solid while the stock trades near fair value.
Six-month rally (CATALYST): A TradingView headline reports a 25.5% gain over six months.
Earnings preview (CATALYST): A Yahoo Finance headline asks whether BDX will beat estimates in its next report.
$19 billion US manufacturing investment (MARKET WIRE): Benzinga and marketscreener.com both report a commitment of $19 billion to expand domestic medical manufacturing.

The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals (supply_chain: NONE), so no butterfly-derived catalysts are available.

Open Questions

What drove the gap between 5.4% revenue growth and a 34.3% earnings decline, and is that gap structural or one-time?
What are the individual 13F and Form 4 transactions underlying the 18/20 whale pillar and 12/20 insider pillar?
What is the FY 2025 EPS and free cash flow, which the financials table leaves unreported?
What is the company's supplier and customer dependency map, given the Butterfly graph shows none?
What specific catalysts would the rating's "Watch for Breakout" verdict require, and what is the timing of the next earnings report referenced in the news?

BDX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Becton Dickinson and Company (BDX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BDX Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 6h ago

Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further?

Yahoo Finance report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Seeking Alpha • 9h ago

Becton, Dickinson: Fundamentals Remain Solid, Trades Near Fair Value (Rating Downgrade)

Seeking Alpha report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 12h ago

BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?

TradingView report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 15h ago

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Yahoo Finance report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18h ago

Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

Benzinga report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 21h ago

Becton Dickinson to invest $19bn in the US

marketscreener.com report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Weekly Recap: $19B U.S. investment and undisclosed agreement impact

TradingView report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Becton, Dickinson and Company (BDX) Stock Forecast and Price Target 2026 $BDX

MarketBeat report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BDX Bull vs. Bear Conversation Board — What's Your Call at $197.88?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BDX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $214.21 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BDX (C+ • RQD 67/100) a Buy at $198.34?

Welcome to the BDX (Becton Dickinson and Company) Roar Pit. Current RQD Composite is 67/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $162.64 (-18.0%)

Spot @ $198.34

Pump the brakes on BDX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BDX, but look at what you are paying: 32.2x trailing P/E with 45.4% gross margins. Unless Becton Dickinson and Company expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $230.07 (+16.0%)

Spot @ $198.34

BDX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BDX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $198.34 (52-wk range $127.59 - $200.47), any beat on forward guidance forces shorts and underweight funds to chase.